Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
← catalyst calendarSponsored by Q32 Bio Inc. (industry) · QTTB — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
102estimated
Sites
24
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-30 | actual | When the study began enrolling |
| Primary completion | Dec 2024 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2024 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: ADX-914
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A only: Safety parameters including incidence of serious adverse events and adverse events of special interest
measured 14 Weeks
Part A and B: Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 14 for ADX-914 vs placebo
measured 14 Weeks
Permalink · QTTB's whole pipeline · Catalyst calendar · Every registered study · What changed